Clinical Trial Update: Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TMX-101 for carcinoma in situ of the bladder and non-muscle-invasive bladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TMX-101

Snippet

Sponsor: Telormedix SA | Conditions: Carcinoma in Situ, Non Muscle Invasive Bladder Cancer | Phase 2 | Status: COMPLETED